OncoInsight
OncoInsight is dedicated to delivering innovative, accessible cell therapies for cancer patients. Their mission is to discover, develop, and deliver novel off-the-shelf NK cell therapy products that have a profound impact on cancer treatment. The company focuses on engineering allogeneic natural killer (NK) cells, CAR-NK cells, and other immune cell therapies, aiming to become a leading innovator in the field of cancer immunotherapy.
Industries
Nr. of Employees
small (1-50)
OncoInsight
5th and 6th Floors, R&D Block, Omnibus Park, 222 Banpo-daero, Seocho-gu, Seoul, 06591, South Korea
Products
Allogeneic NK cell therapy for solid tumors (lead lung cancer indication)
An off-the-shelf, hematopoietic stem cell-derived NK cell therapy candidate developed for treatment of solid tumors, with lung cancer as a lead indication.
CAR-NK therapies targeting gastric cancer and triple-negative breast cancer
CAR-engineered NK cell therapy candidates targeting gastric cancer and triple-negative breast cancer indications.
HSC-derived CAR-NK approach for B cell-driven autoimmune diseases
CAR-modified HSC-derived NK cell candidate designed to target B cell-driven autoimmune conditions such as lupus.
iPSC-derived macrophage-based CAR therapy (CAR-M) co-development
Development program for CAR-engineered iPSC-derived macrophages intended to enhance tumor-specific phagocytosis and anti-tumor immunity; developed in partnership with an external developer.
iPSC-derived mesenchymal (MSC-like) cell therapy for autoimmune disease
A program developing iPSC-derived mesenchymal/stromal cell therapy aimed at treating autoimmune conditions.
Allogeneic NK cell therapy for solid tumors (lead lung cancer indication)
An off-the-shelf, hematopoietic stem cell-derived NK cell therapy candidate developed for treatment of solid tumors, with lung cancer as a lead indication.
CAR-NK therapies targeting gastric cancer and triple-negative breast cancer
CAR-engineered NK cell therapy candidates targeting gastric cancer and triple-negative breast cancer indications.
HSC-derived CAR-NK approach for B cell-driven autoimmune diseases
CAR-modified HSC-derived NK cell candidate designed to target B cell-driven autoimmune conditions such as lupus.
iPSC-derived macrophage-based CAR therapy (CAR-M) co-development
Development program for CAR-engineered iPSC-derived macrophages intended to enhance tumor-specific phagocytosis and anti-tumor immunity; developed in partnership with an external developer.
iPSC-derived mesenchymal (MSC-like) cell therapy for autoimmune disease
A program developing iPSC-derived mesenchymal/stromal cell therapy aimed at treating autoimmune conditions.
Services
Joint research and development agreements to co-develop cell therapy modalities, including division of laboratory and manufacturing responsibilities.
Support for establishing production capacity for cell therapy products, including facility build-out and equipment deployment for large-scale cell production.
Joint research and development agreements to co-develop cell therapy modalities, including division of laboratory and manufacturing responsibilities.
Support for establishing production capacity for cell therapy products, including facility build-out and equipment deployment for large-scale cell production.
Expertise Areas
- NK cell therapy development
- Allogeneic/off-the-shelf cell therapy manufacturing
- CAR engineering of innate immune cells
- iPSC-derived cell therapy development (macrophages, mesenchymal cells)
Key Technologies
- CAR engineering of immune cells
- Hematopoietic stem cell (HSC) to NK cell differentiation
- iPSC-derived macrophage differentiation
- iPSC-derived mesenchymal/stromal cell differentiation
News & Updates
The company raised 21.5 billion KRW in Series A funding, with participation from key investment firms, to accelerate pre-IPO preparations and clinical development.
Preliminary clinical data indicates high efficacy and safety of their CAR-NK therapy in treating solid tumors, with plans for further clinical trials.
OncoInsight is developing advanced immune cell therapies, including CAR-NK and iPSC-derived immune cells, aiming to revolutionize cancer treatment.
Korean biotech companies, including OncoInsight, are making significant progress in cell and gene therapy development, attracting global attention.
Secured Series A funding of 21.5 billion KRW
Successfully raised significant investment to support clinical development and manufacturing capabilities.
Development of CAR-NK cell platform for solid tumors
Established a proprietary platform for off-the-shelf CAR-NK therapies targeting various cancers.
The company raised 21.5 billion KRW in Series A funding, with participation from key investment firms, to accelerate pre-IPO preparations and clinical development.
Preliminary clinical data indicates high efficacy and safety of their CAR-NK therapy in treating solid tumors, with plans for further clinical trials.
OncoInsight is developing advanced immune cell therapies, including CAR-NK and iPSC-derived immune cells, aiming to revolutionize cancer treatment.
Korean biotech companies, including OncoInsight, are making significant progress in cell and gene therapy development, attracting global attention.
Secured Series A funding of 21.5 billion KRW
Successfully raised significant investment to support clinical development and manufacturing capabilities.
Development of CAR-NK cell platform for solid tumors
Established a proprietary platform for off-the-shelf CAR-NK therapies targeting various cancers.